Pillar Biosciences OncoReveal Nexus/MSK-REACT

Pillar Biosciences has launched oncoReveal Nexus, a research-use-only next-generation sequencing-based targeted cancer panel kit. The panel assesses key driver genes for both hematological and solid tumors, and is fully automatable, batching up to 81 patient samples in an Illumina MiSeq run, using as little as 2.5 ng DNA per sample. Reports are issued two to three days after DNA isolation, enabling labs to assess key driver alterations prior to initiating comprehensive genomic profiling, Pillar said.

New York's Memorial Sloan Kettering Cancer Center (MSK), will be the first to use oncoReveal Nexus, branded as MSK-REACT. The new panel, which has received conditional approval from the New York State Department of Health, is expected to help accelerate genomic results in parallel with the comprehensive genomic profiling assay MSK-IMPACT for both solid and hematologic malignancies, Pillar said.